Hetero Received Generic Sofosbuvir (Gilead’s Sovaldi) Approval From Drug Controller General Of India (DCGI)

HYDERABAD, INDIA--(Marketwired - March 12, 2015) -

Hetero, a leading pharmaceutical company based in Hyderabad, India, today announced that it has received approval for generic Sofosbuvir Tablets, 400 mg, from Drug Controller General of India.

Hetero will launch Sofosbuvir under its brand Sofovir in India. Hetero will price its generic medicine at Rs 19,900/- for a bottle of 28 tablets and will launch the medicine this month in India and other countries soon. Hetero has also tied up with various other Licensee holders to distribute the generic Sofosbuvir in India.

Sofosbuvir 400 mg tablets, a once-daily oral dose, is being used for the treatment of chronic hepatitis C infection across the world. This will herald the beginning of a new era in Hepatitis-C treatment.

Hetero has a non-exclusive License Agreement with Gilead Sciences, Ireland to manufacture and sell generic versions of its chronic hepatitis C medicines in 91 developing countries.

“Hepatitis C is a growing public health concern, particularly in developing countries such as India, and Hetero is committed to bringing affordable Sofosbovir to India,” said Vamsi Krishna, Director-Hetero.

About Hetero

Hetero is a leading global pharmaceutical company and provides Custom Pharmaceutical Services. Founded in 1993, Hetero maintains 20 facilities across the globe and markets a portfolio of over 200 products in 138 countries. Hetero’s commitment to reliability, quality, capacity, and value have been a cornerstone since its inception, and the company offers a unique value proposition in its ability to create efficiencies through vertical integration of contract manufacturing services.